BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25450876)

  • 1. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature.
    Kaster TS; Yaremko B; Palma DA; Rodrigues GB
    Clin Lung Cancer; 2015 Mar; 16(2):71-9. PubMed ID: 25450876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)-Lung Working Group.
    Parisi G; Mazzola R; Ciammella P; Timon G; Fozza A; Franceschini D; Navarria F; Bruni A; Perna M; Giaj-Levra N; Alongi F; Scotti V; Trovo M
    Radiol Med; 2019 Feb; 124(2):136-144. PubMed ID: 30368721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
    Kepka L; Tyc-Szczepaniak D; Bujko K
    J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
    Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?
    de Dios NR; Sanz X; Foro P; Membrive I; Reig A; Ortiz A; Jiménez R; Algara M
    Clin Transl Oncol; 2017 Apr; 19(4):440-447. PubMed ID: 27553602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
    Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
    Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer.
    Pollom EL; Qian Y; Durkee BY; von Eyben R; Maxim PG; Shultz DB; Gensheimer M; Diehn M; Loo BW
    Clin Lung Cancer; 2016 Nov; 17(6):588-594. PubMed ID: 27378172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
    Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
    Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
    Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
    Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
    [No Abstract]   [Full Text] [Related]  

  • 11. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
    Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
    Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
    Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature.
    Kong C; Guo WJ; Zha WW; Zhu XZ; Huang SF; Zhang YW; Xu JH; He X
    Lung Cancer; 2014 Apr; 84(1):7-12. PubMed ID: 24548340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
    Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.